BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

Boston Scientific doubles down on mitral valves with $90M investment, option to buy Millipede

Jan. 25, 2018
By Omar Ford
No Comments
Boston Scientific Corp. is taking a deeper dive into the mitral valve space with a $90 million investment and an acquisition option agreement with Millipede Medical Inc. The Santa Rosa, Calif.-based company has developed the Iris transcatheter annuloplasty ring system for the treatment of severe mitral regurgitation.
Read More

JNJ continues turn around of device unit, sees 5.9 percent increase in sales for 4Q17

Jan. 24, 2018
By Omar Ford
No Comments
Johnson & Johnson Corp. brought in about $20.2 billion in sales for 4Q17, beating Wall Street consensus of $20.08 billion. One of the bright spots for Brunswick, N.J.-based Johnson & Johnson was the continued improvement of its medical device division. In 2017, J&J's device offerings increased in sales by about 8.3 percent and brought in about $7 billion. This exceeded analysts' consensus of $6.9 billion.
Read More

Medrobotics stakes claim in surgical robotics space with thoracic procedure indication from FDA

Jan. 23, 2018
By Omar Ford
No Comments
Medrobotics Corp. is expanding into general surgical, gynecological and thoracic procedures with its latest FDA-cleared indication. The Raynham, Mass.-based company's Flex Robotic system previously had indications for oropharynx, hypopharynx and larynx procedures. The company is also pursuing expansion of applications to other areas including transvaginal gynecologic procedures.
Read More

Qiagen's Therascreen wins supplemental PMA to be used as CDx with BI's Gilotrif

Jan. 22, 2018
By Omar Ford
No Comments
Qiagen NV has received an expanded PMA indication for its Therascreen diagnostic test to be used in conjunction with Boehringer Ingleheim GmbH's lung cancer therapy, Gilotrif (afatinib). The approval extends the labeling claim to include detection of EGFR mutations L681Q, G719X and S768I to aid the identification of metastatic non-smal-cell lung cancer (NSCLC) patients for whom Gilotrif is indicated.
Read More

Bluegrass Vascular launches pivotal trial for Surfacer Inside-Out access catheter

Jan. 19, 2018
By Omar Ford
No Comments

Haliodx raises $22.3M in series B to push development of colon cancer diagnostic

Jan. 18, 2018
By Omar Ford
No Comments

Waveform stakes claim in diabetes market, completes initial studies of CGM device

Jan. 17, 2018
By Omar Ford
No Comments

BSX wins FDA nod for Spectra Wavewriter SCS to help treat chronic pain in patients

Jan. 12, 2018
By Omar Ford
No Comments
Boston Scientific Corp. won a nod from the FDA to market its Spectra Wavewriter spinal cord stimulator (SCS) system to treat pain. The Marlborough, Mass.-based company said its SCS works by sending low electrical pulses, which vary in frequency, pulse width and amplitude, to the spinal cord to interrupt pain signals.
Read More

Pulmonx sets sights on PMA for Zephyr endobronchial valve

Jan. 11, 2018
By Omar Ford
No Comments

Carbon copies success of JJDC collaboration with new $200M series D financing imprint

Jan. 10, 2018
By Omar Ford
No Comments
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing